Sustained-release LAI prodrug of buprenorphine(Indivior)
- Generic Name
- Sustained-release LAI prodrug of buprenorphine(Indivior)
INDV-6001 Multiple-Dose Pharmacokinetic Study
Phase 2
Recruiting
- Conditions
- Moderate to Severe Opioid Use Disorder
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT06576843
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Innovative Clinical Research, Inc., Miami Lakes, Florida, United States
🇺🇸Chicago Clinical Research Institute Inc., Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath